There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veracyte (VCYT – Research Report), Krystal Biotech (KRYS – Research Report) and Immatics (IMTX – Research Report) with bullish sentiments.
Veracyte (VCYT)
In a report issued on May 19, Puneet Souda from SVB Securities maintained a Buy rating on Veracyte, with a price target of $35.00. The company’s shares closed last Friday at $24.39.
According to TipRanks.com, Souda is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veracyte with a $31.50 average price target.
See the top stocks recommended by analysts >>
Krystal Biotech (KRYS)
Bank of America Securities analyst Alec Stranahan reiterated a Buy rating on Krystal Biotech on May 19 and set a price target of $118.00. The company’s shares closed last Friday at $96.06, close to its 52-week high of $97.31.
According to TipRanks.com, Stranahan is a 1-star analyst with an average return of
Krystal Biotech has an analyst consensus of Strong Buy, with a price target consensus of $114.60, implying a 29.3% upside from current levels. In a report issued on May 8, Goldman Sachs also maintained a Buy rating on the stock with a $135.00 price target.
Immatics (IMTX)
In a report issued on May 16, Jonathan Chang from SVB Securities reiterated a Buy rating on Immatics, with a price target of $16.00. The company’s shares closed last Friday at $9.77.
According to TipRanks.com, Chang has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immatics with a $18.25 average price target, which is an 88.5% upside from current levels. In a report issued on May 16, Jefferies also maintained a Buy rating on the stock with a $20.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VCYT:
- “The Red Journal” data validate clinical utility of Veracyte prostate classifier
- VCYT Earnings this Week: How Will it Perform?
- Veracyte announces five abstracts to be presented at ASCO
- Veracyte: Decipher Prostate Genomic Classifier may aid prostate cancer treatment
- Veracyte management to meet with William Blair
